Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)
Abstract Selumetinib (AZD6244, ARRY-142886) is a selective, non–ATP-competitive inhibitor of mitogen-activated protein/extracellular signal–regulated kinase kinase (MEK)-1/2. Th...